ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "glucocorticoids"

  • Abstract Number: 2430 • ACR Convergence 2023

    Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

    Beth Wallace1, Yuqing Gao2, H. Myra Kim1, Bryant England3, Joshua Baker4, Brian Sauer5, Grant Cannon6, Punyasha Roul3, Ted R Mikuls7, Shirley Cohen-Mekelburg1, Daniel Clauw8, Wyndy Wiitala2, Rodney Hayward1, Jeremy Sussman1 and Akbar Waljee9, 1VA Ann Arbor; University of Michigan, Ann Arbor, MI, 2VA Ann Arbor, Ann Arbor, MI, 3University of Nebraska Medical Center, Omaha, NE, 4University of Pennsylvania, Philadelphia, PA, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 9VA Ann Arbor, University of Michigan, Ann Arbor, MI

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events…
  • Abstract Number: 0207 • ACR Convergence 2023

    Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis

    Athanasios Vassilopoulos1, Stephanos Vassilopoulos1, Fadi Shehadeh2, Markos Kalligeros1 and Eleftherios Mylonakis3, 1Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, 2Houston Methodist Research Institute, Houston, TX, 3Department of Medicine, Houston Methodist Hospital, Houston, TX

    Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
  • Abstract Number: 1566 • ACR Convergence 2023

    Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

    Christine Xu1, Ying Liu1, Jennifer Sloane2, Remco Diab3, Hubert van Hoogstraten1, Hisham Abdallah4, Sreeraj Macha1 and Bhaskar Dasgupta5, 1Sanofi, Bridgewater, NJ, 2Sanofi, Cambridge, MA, 3Sanofi, Rotkreuz, Switzerland, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Anglia Ruskin University, East Anglia, United Kingdom

    Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
  • Abstract Number: 2516 • ACR Convergence 2023

    The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica

    Katrina Nguyen1, Jennifer Du1, Jiaxiao shi2 and Antony Lin1, 1Kaiser SCAL, Fontana, CA, 2SCPMG, Pasadena, CA

    Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
  • Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium

    Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

    Emily Zhang1, Gabrielle Alonzi1, Madeline Hlobik1, Esra Meidan1, Mindy Lo1, Olha Halyabar2, Melissa Hazen1, Ezra Cohen3, Lauren Henderson1, Siobhan Case4, Margaret Chang1, Camille Frank1, Ankana Daga1, Jonathan Hausmann5, Ahmad Bakhsh1, Liyoung Kim1, Daniel Ibanez1, Holly Wobma1, Mia Chandler6, Fatma Dedeoglu1, Robert Sundel1, Peter Nigrovic1, Karen Costenbader7, Mary Beth Son1 and Joyce Chang1, 1Boston Children's Hospital, Boston, MA, 2Children's Hospital/Boston Medical Center, Boston, MA, 3Boston Medical Center, Boston, MA, 4Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, 5Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, 6Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
  • Abstract Number: L01 • ACR Convergence 2022

    Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study

    Giovanni Adami, Angelo Fassio, Davide Bertelle, Camilla Benini, Davide Gatti and Maurizio Rossini, Rheumatology Unit, University of Verona, Verona, Italy

    Background/Purpose: The recently published GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial has opened the debate around the benefits of glucocorticoids (GCs) in older patients with…
  • Abstract Number: L11 • ACR Convergence 2022

    Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial

    Wai Han Ma1, Chi Chiu Mok2, Ling Yin Ho2, Kar Li Chan3, Sau Mei Tse4 and Sammy Chen5, 1Department of Nuclear Medicine, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Tsing Yi, Hong Kong, 4Department of Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 5Department of Pathology, Hong Kong, Hong Kong

    Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid -induced osteoporosis (GIOP)Methods: Adult patients (≥18 years)…
  • Abstract Number: 0863 • ACR Convergence 2022

    Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study

    Karen James1, George Tomlinson2, Tim Beukelman3, Laura Schanberg4, Anne Dennos5, VIncent Del Gaizo6, Marian Jelinek7, Erin Pfeifer8, Shalini Mohan9 and Yukiko Kimura10, 1University of Utah, Salt Lake City, UT, 2University of Toronto, Toronto, ON, Canada, 3Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, 7Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, 8Genentech, Englewood, NJ, 9Genentech, San Diego, 10Hackensack Meridian Health, New York, NY

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
  • Abstract Number: 1958 • ACR Convergence 2022

    The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry

    Sabine Dieperink1, Bente Glintborg2, Frank Mehnert3, Mette Nørgaard3, Louise Bruun Oestergaard4, Thomas Benfield5, Christian Torp-Pedersen6, Andreas Petersen7 and Merete Lund Hetland1, 1Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, 2Rigshospitalet, Glostrup, Virum, Denmark, 3Aarhus University Hospital, Aarhus, Denmark, 4Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark, 5Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark, 6Copenhagen University Hospital - North Zealand, Copenhagen, Denmark, 7Statens Serum Institut, Copenhagen, Denmark

    Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…
  • Abstract Number: 0955 • ACR Convergence 2022

    Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort

    SABRINA HAMROUN1, Marion Couderc2, Rene-Marc Flipo3, Laure Gossec4, Christophe Richez5, Rakiba Belkhir6, Aline Frazier-Mironer7, Valerie Devauchelle8, Hubert Marotte9, Jérémie SELLAM10, elisabeth gervais11, Alban DEROUX12, Cédric Lukas13, Emmanuelle Dernis14, Emmanuel Chatelus15 and Anna Molto16, 1Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, 2University Hospital, Clermont-Ferrand, France, 3CHU Lille, Boulogne-Billancourt, France, 4Sorbonne Université, Paris, France, 5Université de Bordeaux, Bordeaux, France, 6Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 7APHP Hôpital Lariboisire, Paris, France, 8Université de Bretagne Occidentale, Brest, France, 9INSERM 1059, Saint-Etienne, France, 10Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, 11chu poitiers, Poitiers, France, 12CHU Grenoble, Grenoble, France, 13University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 14LE MANS general hospital, LE MANS, France, 15University Hospital of Strasbourg, Strasbourg, France, 16Rheumatology Department, Cochin Hospital, APHP, Paris, France

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge…
  • Abstract Number: 1987 • ACR Convergence 2022

    Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study

    CF Allaart1, Sytske Anne Bergstra2, Tom Huizinga1 and Joy van der Pol3, 1Leiden University Medical Center, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Leiden University Medical Center, Utrecht, Netherlands

    Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…
  • Abstract Number: 0021 • ACR Convergence 2022

    DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease

    Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China

    Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…
  • Abstract Number: 0960 • ACR Convergence 2022

    Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus

    Hiromi Shimada1, Risa Wakiya1, shusaku nakashima2, Mikiya Kato1, taichi miyagi3, Yusuke Ushio4, Koichi Sugihara5, Rina Mino6, mao mizusaki6, Kanako Chujo7, Tomohiro Kameda1 and Hiroaki Dobashi8, 1Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 3Kagawa University, Kidagun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 5Kagawa University, Miki-cho, Kita-gun, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

    Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy…
  • Abstract Number: 1994 • ACR Convergence 2022

    Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?

    Lotte van Ouwerkerk1, Sytske Anne Bergstra2, Tjardo Maarseveen1, Rachel Knevel1, Tom Huizinga1 and CF Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…
  • Abstract Number: 0128 • ACR Convergence 2022

    Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015

    Sho Fukui1, Takehiro Nakai2, Satoshi Kawaai3, Yukihiko Ikeda2, Masei Suda4, Atsushi Nomura5, Hiromichi Tamaki2, Mitsumasa Kishimoto6, Sachiko Ohde7 and Masato Okada2, 1Kyorin University Hospital, Tokyo, Japan, 2St. Luke's International Hospital, Tokyo, Japan, 3St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 4Suwa Central Hospital, Nagano, Japan, 5St. Luke's International Hospital, Nagareyama, Japan, 6Kyorin University School of Medicine, Yokohama, Japan, 7Center for Clinical Epidemiology, St.Luke's International University, Tokyo, Japan

    Background/Purpose: Alternate-day glucocorticoid (GC) treatment is an effective treatment option that can reduce GC-associated adverse events in patients with rheumatoid arthritis and other autoimmune rheumatic…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology